{"id":726704,"date":"2023-01-30T07:04:45","date_gmt":"2023-01-30T12:04:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/"},"modified":"2023-01-30T07:04:45","modified_gmt":"2023-01-30T12:04:45","slug":"first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/","title":{"rendered":"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BOCA RATON, Fla., Jan.  30, 2023  (GLOBE NEWSWIRE) &#8212; First Wave BioPharma, Inc. (NASDAQ:FWBI) (\u201cFirst Wave BioPharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for\u00a0gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO &amp; Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.<\/p>\n<p>Details of the presentation are as follows:\u00a0<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Event:<\/strong>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">BIO CEO &amp; Investor Conference<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Date:<\/strong>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Monday, February 6, 2023\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Time:<\/strong>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">9:30 a.m., EST\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Location:<\/strong>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Winter Garden Room, Marriott Marquis, New York City<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">During the conference, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company\u2019s business and clinical development strategy, recent corporate achievements, and anticipated milestones.<\/p>\n<p align=\"justify\">\n        <strong>About First Wave BioPharma, Inc.<\/strong><br \/>\n        <br \/>First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical-stage programs built around its two proprietary technologies \u2013 the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn\u2019s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3RDaiwggEaYV_5eFkSs0TuYy2r9x-s1Fm3iNWsvYD3KcmyCj156Xw7aC35Pr6TEVrdNVpV4qccooA6fgfW1x8FQsp49tdH1G_n9E1jXwe8s=\" rel=\"nofollow noopener\" target=\"_blank\">www.firstwavebio.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statement<br \/><\/strong><br \/>\n        <em>This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company\u2019s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the contemplated offering will be successful and whether the Company will be able to regain and maintain compliance with Nasdaq\u2019s continued listing criteria; the size of the potential markets for the Company\u2019s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company\u2019s business, operating results and financial prospects; and the Company\u2019s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company\u2019s financial results are contained in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2021 under the heading \u201cRisk Factors,\u201d as well as the Company\u2019s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.<\/em>\n      <\/p>\n<p>\n        <strong>For more information:<\/strong><br \/>\n        <br \/>First Wave BioPharma, Inc.<br \/>777 Yamato Road, Suite 502<br \/>Boca Raton, FL 33431<br \/>Phone: (561) 589-7020<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GMhcvZfjIDIAbj_u2bTVBUFnbe6-xWzQQMXQ-S3TFvWdwE5lfDc_2oRjMm8z1vaI3WVQ4hlwPjVgqUNjozQNH_En6Mog0oIQLnJb66DmjNU=\" rel=\"nofollow noopener\" target=\"_blank\">info@firstwavebio.com<\/a><\/p>\n<p>Media contact:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lvAvKlLiSprOnQI8on9hdJUCQjPjEz5tcsUQhaQnxkNok3RTVbQR4dHZzqyya7N3q29mA8v2IkWNAPQiK2RqXwRAfyACnLbb5Q9Nz0SV58Q=\" rel=\"nofollow noopener\" target=\"_blank\">Tiberend Strategic Advisors, Inc.<\/a><br \/>David Schemelia<br \/>(609) 468-9325<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V-MV73uobJRw88cZjhHxqRsTa-6pYfwJL6-syArDcp8B5jX5gvNmwdmdoF7oBWWOopRP3BBPQRBAOEFQA_oI2jkPuS2MN1G_MkA0R4yRtxE=\" rel=\"nofollow noopener\" target=\"_blank\">dschemelia@tiberend.com<\/a><\/p>\n<p>Bill Borden<br \/>(732) 910-1620<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OLQ5HIY8RQIem2_APiK-jHErPasykrE5j1tFhfUDxiv4pOsVv2tre47sft__nt3L1dD7wAwaT_W6pQQcWnTJAuBubYgLxfDVVlMHJAh1OM4=\" rel=\"nofollow noopener\" target=\"_blank\">bborden@tiberend.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzYyY2M5NTktNDBjOC00ZDI2LTkzMWYtMDlmYzMxOWVmZWFiLTEwOTM3Nzg=\/tiny\/First-Wave-BioPharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; First Wave BioPharma, Inc. (NASDAQ:FWBI) (\u201cFirst Wave BioPharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for\u00a0gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO &amp; Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as follows:\u00a0 Event:\u00a0 BIO CEO &amp; Investor Conference Date:\u00a0 Monday, February 6, 2023\u00a0 Time:\u00a0 9:30 a.m., EST\u00a0 Location:\u00a0 Winter Garden Room, Marriott Marquis, New York City During the conference, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company\u2019s business &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-726704","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; First Wave BioPharma, Inc. (NASDAQ:FWBI) (\u201cFirst Wave BioPharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for\u00a0gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO &amp; Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as follows:\u00a0 Event:\u00a0 BIO CEO &amp; Investor Conference Date:\u00a0 Monday, February 6, 2023\u00a0 Time:\u00a0 9:30 a.m., EST\u00a0 Location:\u00a0 Winter Garden Room, Marriott Marquis, New York City During the conference, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company\u2019s business &hellip; Continue reading &quot;First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-30T12:04:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference\",\"datePublished\":\"2023-01-30T12:04:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/\"},\"wordCount\":640,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/\",\"name\":\"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=\",\"datePublished\":\"2023-01-30T12:04:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference - Market Newsdesk","og_description":"BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; First Wave BioPharma, Inc. (NASDAQ:FWBI) (\u201cFirst Wave BioPharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for\u00a0gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO &amp; Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as follows:\u00a0 Event:\u00a0 BIO CEO &amp; Investor Conference Date:\u00a0 Monday, February 6, 2023\u00a0 Time:\u00a0 9:30 a.m., EST\u00a0 Location:\u00a0 Winter Garden Room, Marriott Marquis, New York City During the conference, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company\u2019s business &hellip; Continue reading \"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-30T12:04:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference","datePublished":"2023-01-30T12:04:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/"},"wordCount":640,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/","name":"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=","datePublished":"2023-01-30T12:04:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTY2OSM1MzcyMDU3IzIwODIyMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-to-present-at-the-bio-ceo-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"First Wave BioPharma to Present at the BIO CEO &amp; Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=726704"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726704\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=726704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=726704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=726704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}